Newly matched donor-derived CD5 CAR T-cells
Sponsors
Beijing GoBroad Hospital
Conditions
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-Cell Acute Lymphocytic LeukemiaT-cell Malignancies
Phase 1
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
RecruitingNCT06316856
Start: 2024-06-18End: 2026-12-30Target: 54Updated: 2026-03-10
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
RecruitingNCT07070323
Start: 2025-07-09End: 2026-12-31Target: 54Updated: 2025-11-26